Literature DB >> 6185902

Retinal ischemia and risk of neovascularization following central retinal vein obstruction.

L E Magargal, L A Donoso, G E Sanborn.   

Abstract

The predominant risk factor for the development of neovascular complications involving the retina (NVR), the optic disc (NVD), and iris (NVI) following central retinal vein obstruction (CRVO) is the extent, location, and duration of retinal ischemia (ischemic drive). The extent of retinal capillary nonperfusion (ischemic index) was quantitated by microcomputer analysis of 200 standard fundus-iris fluorescein angiograms. The results were correlated with the development of neovascularization in eyes not receiving prophylactic argon laser panretinal photocoagulation (PRP). Of the 85 eyes with intact capillary perfusion (hyperpermeable group), none developed NVR/NVD and only one eye (1%) developed neovascular glaucoma (NVG). Twenty-nine eyes exhibited moderate degrees of retinal ischemia (indeterminate group), and three eyes (10%) developed NVR/NVD, with two eyes (7%) developing NVG. Of the 86 eyes with extensive retinal capillary nonperfusion (ischemic group), 28 eyes (33%) developed NVR/NVD and NVG occurred in 39 eyes (45%). The inherent difficulties in following high risk patients clinically and angiographically at frequent intervals over extended periods of time, the tendency for rapid progression of early NVI to NVG, and the relatively poor results following treatment in advanced cases make the early recognition of eyes at high risk to develop NVG essential and the initiation of prophylactic PRP as the treatment of choice in this disorder.

Entities:  

Mesh:

Year:  1982        PMID: 6185902     DOI: 10.1016/s0161-6420(82)34655-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

1.  Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion.

Authors:  C Hvarfner; A Hillarp; J Larsson
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

2.  Neovascular response in ischaemic central retinal vein occlusion after panretinal photocoagulation.

Authors:  I E Murdoch; P H Rosen; J S Shilling
Journal:  Br J Ophthalmol       Date:  1991-08       Impact factor: 4.638

Review 3.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

4.  Electroretinogram as indicator of prognosis of central retinal vein occlusion.

Authors:  M F Cordeiro; M Stanford; J S Shilling; G E Holder
Journal:  Br J Ophthalmol       Date:  1995-05       Impact factor: 4.638

5.  Chronic ocular ischaemia.

Authors:  S S Hayreh
Journal:  Br J Ophthalmol       Date:  1985-08       Impact factor: 4.638

6.  Clinical progress in impending central retinal vein occlusion.

Authors:  Dong-Hoon Lee; Seok-Joon Lee; Ie-Na Yoon
Journal:  Korean J Ophthalmol       Date:  2010-04-06

7.  Long-term effects of radial optic neurotomy for central retinal vein occlusion consecutive interventional case series.

Authors:  Susanne Binder; Tina Aggermann; Simon Brunner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-04       Impact factor: 3.117

8.  Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase.

Authors:  S S Hayreh; M R Klugman; M Beri; A E Kimura; P Podhajsky
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

9.  A prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) study group.

Authors:  Tina Aggermann; Simon Brunner; Ilse Krebs; Paulina Haas; Irene Womastek; Werner Brannath; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-08       Impact factor: 3.117

10.  Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization.

Authors:  Sean F Hackett; Jie Fu; Yoo Chun Kim; Hiroki Tsujinaka; Jikui Shen; Raquel Lima E Silva; Mahmood Khan; Zibran Hafiz; Tao Wang; Matthew Shin; Nicole M Anders; Ping He; Laura M Ensign; Justin Hanes; Peter A Campochiaro
Journal:  Biomaterials       Date:  2020-03-04       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.